# NIH Reporter #3U19CA264512-05S1

Tasquinimod as an adjunct to immunotherapies administered peri-operatively

**Recipient:** Not specified

**Award Amount:** $680,856.00
**Ceiling:** $680,856.00

**Awarded:** September 18, 2026

**Identifier:** 3U19CA264512-05S1

Research grant awarded by the National Cancer Institute to develop tasquinimod as an adjunct immunotherapy for glioblastoma, including phase I and preclinical studies to enhance immunotherapy efficacy.

### Description

This is a research grant project focused on developing tasquinimod as an adjunct immunotherapy for glioblastoma, with a focus on controlling cerebral edema and enhancing immunotherapy efficacy. The project involves a phase I safety and feasibility study, preclinical in vivo studies, and aims to support future clinical trials.

[View original record](https://reporter.nih.gov/search/IgE1H2ioLUOz0qmA4MDg0Q/project-details/11618498)